|
1
|
Qaddoumi I, Sultan I and Gajjar A: Outcome
and prognostic features in pediatric gliomas: A review of 6212
cases from the surveillance, epidemiology, and end results
database. Cancer. 115:5761–5770. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McCarthy BJ, Shibui S, Kayama T, Miyaoka
E, Narita Y, Murakami M, Matsuda A, Matsuda T, Sobue T, Palis BE,
et al: Primary CNS germ cell tumors in Japan and the United States:
An analysis of 4 tumor registries. Neurol Oncol. 14:1194–1200.
2012. View Article : Google Scholar
|
|
3
|
Ye ZN, Liu JP, Wu LY, Zhang XS, Zhuang Z,
Chen Q, Lu Y, Liu CG, Zhang ZH, Zhang HS, et al: Retraction notice
to ‘Downregulation of miR-204 expression correlates with poor
clinical outcome of glioma patients’ [Hum Pathol 2017; 63: 46–52].
Hum Pathol. 63:R12017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Keller M, Rüegg A, Werner S and Beer HD:
Active caspase-1 is a regulator of unconventional protein
secretion. Cell. 132:818–831. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Berges R, Balzeau J, Peterson AC and Eyer
J: A tubulin binding peptide targets glioma cells disrupting their
microtubules, blocking migration, and inducing apoptosis. Mol Ther.
20:1367–1377. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li B, Huang MZ, Wang XQ, Tao BB, Zhong J,
Wang XH, Zhang WC and Li ST: TMEM140 is associated with the
prognosis of glioma by promoting cell viability and invasion. J
Hematol Oncol. 8:892015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Z, Guo Q, Wang R, Xu G, Li P, Sun Y,
She X, Liu Q, Chen Q, Yu Z, et al: The D domain of LRRC4 anchors
ERK1/2 in the cytoplasm and competitively inhibits MEK/ERK
activation in glioma cells. J Hematol Oncol. 9:1302016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang X, Yang H, Gong B, Jiang C and Yang
L: Combined gene expression and protein interaction analysis of
dynamic modularity in glioma prognosis. J Neurooncol. 107:281–288.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fabian MR and Sonenberg N: The mechanics
of miRNA-mediated gene silencing: A look under the hood of miRISC.
Nat Struct Mol Biol. 6:586–593. 2012. View Article : Google Scholar
|
|
10
|
Samir M, Vaas LA and Pessler F: MicroRNAs
in the host response to viral infections of veterinary importance.
Front Vet Sci. 3:862016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou W, Zou B, Liu L, Cui K, Gao J, Yuan S
and Cong N: MicroRNA-98 acts as a tumor suppressor in
hepatocellular carcinoma via targeting SALL4. Oncotarget.
7:74059–74073. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Choi E, Choi E and Hwang KC: MicroRNAs as
novel regulators of stem cell fate. World J Stem Cells. 5:172–187.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang R, Liu C, Niu Y, Jing Y, Zhang H,
Wang J, Yang J, Zen K, Zhang J, Zhang CY and Li D: MicroRNA-128-3p
regulates mitomycin C-induced DNA damage response in lung cancer
cells through repressing SPTAN1. Oncotarget. 8:58098–58107.
2016.PubMed/NCBI
|
|
14
|
Huang CY, Huang XP, Zhu JY, Chen ZG, Li
XJ, Zhang XH, Huang S, He JB, Lian F, Zhao YN and Wu GB: miR-128-3p
suppresses hepatocellular carcinoma proliferation by regulating
PIK3R1 and is correlated with the prognosis of HCC patients. Oncol
Rep. 33:2889–2898. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu D, Green B, Marrone A, Guo Y, Kadlubar
S, Lin D, Fuscoe J, Pogribny I and Ning B: Suppression of CYP2C9 by
microRNA hsa-miR-128-3p in human liver cells and association with
hepatocellular carcinoma. Sci Rep. 5:85342015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mets E, Van Peer G, Van der Meulen J,
Boice M, Taghon T, Goossens S, Mestdagh P, Benoit Y, De Moerloose
B, Van Roy N, et al: MicroRNA-128-3p is a novel oncomiR targeting
PHF6 in T-cell acute lymphoblastic leukemia. Haematologica.
99:1326–1333. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Easwaran H, Tsai HC and Baylin SB: Cancer
epigenetics: Tumor heterogeneity, plasticity of stem-like states,
and drug resistance. Mol Cell. 54:716–727. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hu S, Chen H, Zhang Y, Wang C, Liu K, Wang
H and Luo J: MicroRNA-520c inhibits glioma cell migration and
invasion by the suppression of transforming growth factor-β
receptor type 2. Oncol Rep. 37:1691–1697. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim SJ, Hwang E, Yi SS, Song KD, Lee HK,
Heo TH, Park SK, Jung YJ and Jun HS: Sea buckthorn leaf extract
inhibits glioma cell growth by reducing reactive oxygen species and
promoting apoptosis. Appl Biochem Biotechnol. 182:1663–1674. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Oliveira KA, Dal-Cim T, Lopes FG, Ludka
FK, Nedel CB and Tasca CI: Atorvastatin promotes cytotoxicity and
reduces migration and proliferation of human A172Glioma cells. Mol
Neurobiol. 55:1509–1523. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dang X, Ma A, Yang L, Hu H, Zhu B, Shang
D, Chen T and Luo Y: MicroRNA-26a regulates tumorigenic properties
of EZH2 in human lung carcinoma cells. Cancer Genet. 205:113–123.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qi P, Cheng SQ, Wang H, Li N, Chen YF and
Gao CF: Serum microRNAs as biomarkers for hepatocellular carcinoma
in Chinese patients with chronic hepatitis B virus infection. PLoS
One. 6:e284862011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shao XJ, Miao MH, Xue J, Xue J, Ji XQ and
Zhu H: The down-regulation of microrna-497 contributes to cell
growth and cisplatin resistance through PI3K/akt pathway in
osteosarcoma. Cell Physiol Biochem. 36:2051–2062. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu YH, Li B, Meng FG and Qiu L:
MiR-508-5p is a prognostic marker and inhibits cell proliferation
and migration in glioma. Eur Rev Med Pharmacol Sci. 21:76–81.
2017.PubMed/NCBI
|
|
26
|
Zhu D, Tu M, Zeng B, Cai L, Zheng W, Su Z
and Yu Z: Up-regulation of miR-497 confers resistance to
temozolomide in human glioma cells by targeting mTOR/Bcl-2. Cancer
Med. 6:452–462. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma J, Yu J, Liu J, Yang X, Lou M, Liu J,
Feng F, Ji P and Wang L: MicroRNA-302a targets GAB2 to suppress
cell proliferation, migration and invasion of glioma. Oncol Rep.
37:1159–1167. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ibarrola-Villava M, Llorca-Cardeñosa MJ,
Tarazona N, Mongort C, Fleitas T, Perez-Fidalgo JA, Roselló S,
Navarro S, Ribas G and Cervantes A: Deregulation of ARID1A, CDH1,
cMET and PIK3CA and target-related microRNA expression in gastric
cancer. Oncotarget. 6:26935–26945. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yue W, Wang T, Zachariah E, Lin Y, Yang
CS, Xu Q, DiPaola RS and Tan XL: Transcriptomic analysis of
pancreatic cancer cells in response to metformin and aspirin: An
implication of synergy. Sci Rep. 5:133902015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stearns TM, Cario CL, Savage HS, Sundberg
JP, Paigen B and Berndt A: Early gene expression differences in
inbred mouse strains with susceptibility to pulmonary adenomas. Exp
Mol Pathol. 93:455–461. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mori Y, Olaru AV, Cheng Y, Agarwal R, Yang
J, Luvsanjav D, Yu W, Selaru FM, Hutfless S, Lazarev M, et al:
Novel candidate colorectal cancer biomarkers identified by
methylation microarray-based scanning. Endocr Relat Cancer.
18:465–478. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang N, Eijsink JJ, Lendvai A, Volders HH,
Klip H, Buikema HJ, van Hemel BM, Schuuring E, van der Zee AG and
Wisman GB: Methylation markers for CCNA1 and C13ORF18 are strongly
associated with high-grade cervical intraepithelial neoplasia and
cervical cancer in cervical scrapings. Cancer Epidemiol Biomarkers
Prev. 18:3000–3007. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang CY, Yu HS, Lai TY, Yeh YL, Su CC,
Hsu HH, Tsai FJ, Tsai CH, Wu HC and Tang CH: Leptin increases
motility and integrin up-regulation in human prostate cancer cells.
J Cell Physiol. 226:1274–1282. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang SN, Chen HT, Tsou HK, Huang CY, Yang
WH, Su CM, Fong YC, Tseng WP and Tang CH: Leptin enhances cell
migration in human chondrosarcoma cells through OBRl leptin
receptor. Carcinogenesis. 30:566–574. 2009. View Article : Google Scholar : PubMed/NCBI
|
